This Article Abstract Full Text Full Text (PDF) Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Marcus, G. M. Search for Related Content PubMed PubMed Citation Articles by Marcus, G. M. Related Collections Related Articles

Efficacy of Antiarrhythmic Drugs in Arrhythmogenic Right Ventricular Cardiomyopathy

A Report From the North American ARVC Registry

Gregory M. Marcus, MD^_*,_*, David V. Glidden, PhD, Bronislava Polonsky, MS, Wojciech Zareba, MD, PhD, Lisa M. Smith, MPH^_*, David S. Cannom, MD, N.A. Mark Estes, III, MD^||, Frank Marcus, MD^¶, Melvin M. Scheinman, MD^_* for the Multidisciplinary Study of Right Ventricular Dysplasia Investigators

^_* Division of Cardiology, Electrophysiology Section, University of California, San Francisco, California
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York
Good Samaritan Hospital, Los Angeles, California
^|| Tufts University School of Medicine, Boston, Massachusetts
^¶ Sarver Heart Center, University of Arizona College of Medicine, Tucson, Arizona

View larger version (14K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Timeline of Antiarrhythmic Medicine Use in the 10 ARVC Patients Who Received Amiodarone at Any Time During Study Follow-Up Each patient is represented by a different number (1 to 10). Vertical gray lines represent episodes of either sustained ventricular tachycardia or implantable cardioverter-defibrillator (ICD) therapy. *ICD shock. ARVC = arrhythmogenic right ventricular cardiomyopathy.